Together, the reduced gene expression of an innate immune modulator (SPP1) and a genetically implicated protein (ApoE) by metformin in human neural cells suggest candidate CSF biomarkers, which if validated, may associate with the delayed onset of clinical symptoms of dementia in type 2-diabetic patients. This evidence concerns the gene APOE and dementia.